Dalotuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dalotuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target IGF-1 receptor
Clinical data
ATC code none
Identifiers
CAS Number 1005389-60-5 N
ChemSpider none
UNII 6YI1L648RH YesY
Chemical and physical data
Formula C6528H10086N1730O2018S40
Molar mass 146.4 kg/mol
 NYesY (what is this?)  (verify)

Dalotuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]

Dalotuzumab was developed by Merck & Co., Inc.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab" (PDF). American Medical Association.